BackStoke Therapeutics Overview
Stoke Therapeutics Inc

Stoke Therapeutics Target Price

Where could STOK trade next? Consensus target price: $51.

Get informed when a big investor buys or sells

+ Follow

Share Price

$29.6

Average Target Price

$51.0072.3% upside

2 analysts in the last 4 months

High: $58 | Low: $44

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Canaccord GenuitySumant Kulkarni$5895.9% upsideOpen
2026-07-13Goldman SachsKevin Strang$4448.6% upsideOpen
2026-02-23Wolfe Research$4035.1% upsideOpen
2026-02-05GuggenheimYatin Suneja$60102.7% upsideOpen
2026-01-12Wedbush$3621.6% upsideOpen
2026-01-05Canaccord Genuity$3621.6% upsideOpen
2026-01-05Loop Capital MarketsKeay Nakae$3518.2% upsideOpen
2025-12-16H.C. WainwrightAndrew Fein$5068.9% upsideOpen
2025-12-15UBS$5068.9% upsideOpen
2025-11-05Canaccord Genuity$285.4% downsideOpen
2025-10-10Needham$3518.2% upsideOpen
2025-08-18BTIGThomas Shrader$285.4% downsideOpen
2024-10-11Leerink PartnersMarc Goodman$1839.2% downsideOpen
2024-09-11H.C. WainwrightDebjit Chattopadhyay$3518.2% upsideOpen
2024-05-07Canaccord GenuitySumant Kulkami$2032.4% downsideOpen
2024-03-26NeedhamJoseph Stringer$2225.7% downsideOpen
2024-03-26Canaccord GenuitySumant Kulkami$2129.1% downsideOpen
2022-11-14Needham$2515.5% downsideOpen
2021-04-26Credit SuisseJudah Frommer$5895.9% upsideOpen

Stoke Therapeutics (STOK) FAQ

Stoke Therapeutics posts a target price of $51. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $51 for STOK means covering analysts, on average, see the stock 72.3% upside of $29.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for STOK's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Stoke Therapeutics's other metric pages and overview cover the third.

Judging Stoke Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $51 here, then scan peer and history charts to see if the gap is persistent.